CJC-1295 with IPA

Price range: R800,00 through R1 200,00

CJC-1295 + Ipamorelin

  • What it is: A combination of CJC-1295, a long-acting growth-hormone-releasing hormone (GHRH) analogue, and ipamorelin, a growth-hormone-releasing peptide (GHRP). Together, they are intended to stimulate the body’s own growth-hormone secretion.

  • Commonly marketed for: Increased growth hormone (GH) and IGF-1 levels, muscle recovery, improved body composition, sleep, and potentially fat loss.

  • How it’s purported to work: CJC-1295 stimulates the pituitary through the GHRH pathway, while ipamorelin stimulates GH release through the ghrelin/GHS receptor pathway. The two mechanisms are therefore intended to complement one another.

  • Evidence: CJC-1295 has demonstrated sustained increases in GH and IGF-1 in small human studies, but evidence for meaningful improvements in muscle mass, fat loss, recovery, or other performance outcomes is limited. Evidence specifically supporting the CJC-1295 + ipamorelin combination is also limited.

  • Key risks/side effects: Increasing GH/IGF-1 can potentially contribute to fluid retention, glucose intolerance, and other GH-related effects. FDA has also identified safety concerns surrounding compounded CJC-1295, including immunogenicity and reported systemic reactions. For ipamorelin, FDA notes limited safety information for subcutaneous administration and concerns regarding peptide impurities/immunogenicity.

  • Regulatory status: Neither CJC-1295 nor ipamorelin is an FDA-approved treatment for growth-hormone deficiency. FDA materials note that clinical evidence for CJC-1295 has largely involved healthy adults rather than patients with confirmed GH deficiency.

  • Bottom line: CJC-1295 + ipamorelin is an experimental GH-secretagogue combination with evidence that CJC-1295 can raise GH/IGF-1 levels, but there is insufficient clinical evidence to establish that the combination provides the broader recovery, muscle-building, or fat-loss benefits commonly marketed.

Description

CJC-1295 + IPAMORELIN – ADVANCED GROWTH HORMONE SUPPORT COMPLEX

Elevate Wellness Hub’s CJC-1295 + Ipamorelin peptide complex combines two investigational peptides that act through complementary growth-hormone pathways. The combination is being explored for its potential role in growth-hormone signalling, body composition, recovery, and healthy aging.

KEY BENEFITS

  • Supports research into natural growth-hormone signalling

  • Investigated for muscle and lean-body-mass pathways

  • Supports research into recovery and tissue repair

  • Investigated for body-composition and metabolic pathways

  • Supports research into sleep and physiological recovery

  • Being studied in the context of healthy aging

WHO MAY BENEFIT?

Individuals interested in research into growth-hormone signalling, Those exploring peptide-based recovery research, Individuals studying muscle and body-composition pathways, People interested in research surrounding physiological recovery and healthy aging.

Always use under the guidance of a qualified healthcare professional.

HOW IT MAY HELP

  • CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and has been investigated for its ability to stimulate growth-hormone secretion

  • Ipamorelin is a growth-hormone secretagogue that acts through the ghrelin receptor pathway

  • The two compounds affect complementary pathways involved in growth-hormone signalling

  • Research has explored their potential relationship with IGF-1, body composition, recovery, and metabolic processes

  • The combination is commonly investigated as a means of influencing endogenous growth-hormone pathways

The clinical evidence supporting CJC-1295 + Ipamorelin as a combined treatment for wellness, anti-aging, muscle growth, or recovery remains limited.

POSSIBLE SIDE EFFECTS

Potential adverse effects may include:

  • Headache

  • Dizziness

  • Nausea

  • Fatigue

  • Injection-site reactions

  • Fluid retention or swelling

  • Changes in blood-glucose regulation

  • Increased appetite

  • Tingling or numbness

Because these peptides influence growth-hormone signalling, inappropriate use may potentially affect glucose metabolism, fluid balance, and other hormone-related processes.

NOT SUITABLE FOR

  • Pregnancy or breastfeeding

  • Anyone with a known allergy or sensitivity to either peptide or any ingredient

  • Children unless specifically prescribed and supervised by a paediatric endocrinology specialist

  • Individuals with active or suspected cancer without specialist medical assessment

  • Individuals with uncontrolled diabetes or significant metabolic disorders without appropriate medical supervision

  • Anyone with significant endocrine or pituitary disorders without specialist assessment

  • Anyone using other growth-hormone– or hormone-affecting medicines without professional medical guidance

IMPORTANT DISCLAIMER

CJC-1295 + Ipamorelin is an investigational peptide combination and should not be represented as an approved anti-aging, muscle-building, fat-loss, or recovery treatment.

The individual peptides act on growth-hormone pathways, but the safety and effectiveness of the combination for general wellness purposes have not been established through adequate large-scale clinical trials. FDA has also identified limited safety information and potential concerns regarding compounded CJC-1295 and ipamorelin products.

Elevate Wellness Hub does not represent this product as a substitute for approved medical therapy. Any use must comply with applicable laws and regulations and should only occur under appropriate qualified healthcare-professional supervision or within an authorised research setting.

The 10 mg listed by Elevate Wellness Hub refers to the product strength and is not a dosing recommendation.

It’s not just about feeling better, it’s about elevating your quality of life.

ELEVATE WELLNESS HUB – PEPTIDE WELLNESS – SCIENCE BACKED. RESULTS DRIVEN. YOU ELEVATED.

Additional information

Weight N/A
Type

VIAL, PEN

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 with IPA”

Your email address will not be published. Required fields are marked *